Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong
· Delayed Price · Currency is HKD 76.20
-1.35 (-1.74%)
Apr 29, 2026, 4:08 PM HKT
Shanghai Henlius Biotech Revenue
In the year 2025, Shanghai Henlius Biotech had annual revenue of 6.67B CNY with 16.46% growth. Shanghai Henlius Biotech had revenue of 3.85B in the half year ending December 31, 2025, with 32.91% growth.
Revenue
6.67B CNY
Revenue Growth
+16.46%
P/S Ratio
5.58
Revenue / Employee
1.77M CNY
Employees
3,762
Market Cap
41.41B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Junshi Biosciences | 2.78B |
| Biocytogen Pharmaceuticals (Beijing) | 1.78B |
| 3SBio | 19.69B |
| Genscript Biotech | 7.47B |
| InnoCare Pharma | 2.87B |
| Shanghai Bao Pharmaceuticals | 54.70M |
| Duality Biotherapeutics | 2.06B |
| RemeGen | 3.62B |
Shanghai Henlius Biotech News
- 3 months ago - Shanghai Henlius Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts